© Borgis - Medycyna Rodzinna 3, p. 77-80
Wojciech Cielica1, *Agnieszka Sajdak-Wojtaluk1, Grażyna Chodorowska2, Agnieszka Barczyk1
Przypadek półpaśca uogólnionego zgorzelinowego i krwotocznego u pacjenta w przebiegu białaczki limfatycznej typu B
The generalized gangrenous and haemorrhagic shingles at the patient in course of lymphatic leukaemia of the type B
1 Oddział Dermatologiczny 1. Szpitala Wojskowego w Lublinie
Ordynator Oddziału: lek med. Krystyna Bańka
2 Klinika Dermatologiczna Uniwerstytetu Medycznego w Lublinie
Kierownik Kliniki: prof. dr hab. n. med. Grażyna Chodorowska
Summary
The shingles (Herpes Zoster) it is the sharp infectious disease, that is caused by the Varicella Zoster virus which is also the cause of smallpox disease. After the primary infection the virus stays in form of latency in rolls of cranial nerves, in the rolls of spinal ganglion or the nerves of the peripheral nervous system. The development of shingles (Herpes Zoster) starts after a period of few weeks or even after a few years as a result of activitating delatescent contagion and the development of infectious changes. The factors initiating virus´ activations can be, among others, UV radiation psychical or mechanical injury, infections, neoplasmic diseases (cancers), immunosuppressive treatment, X-ray therapy. It´s a neurotropic virus that main characteristic are skin changes corresponding with the nervure of one (or several) back roots (segments). At older people, due to natural involution of immunological system and the occurance of the diseases disadvantaging natural immunity, the shingles is comparatively frequent. In this ill´s group the course of contagion is heavier, it requires more intensive treatment and is more often complicated by the long-term neuralgias. In this thesis the generalized gangrenous and haemorrhagic shingles was introduced at the patient in course of lymphatic leukaemia of the type B. The special attention was paid on the clinical presentment/image and the therapeutic treatment. As a result of applied general pharmacotherapy profitable effects of treatment were received.
Key words: herpes zoster, reactivation, treatment
Piśmiennictwo
1. O. Braun Falco, Dermatologia t. 1. 2. Jabłońska S., Majewski S. Choroby skóry i choroby przenoszone drogą płciową, 2005, str. 108-110. 3. Arvin AM, Varicella-zoster virus: overview and clinical manifestations, Semin Dermatol, 1996 Jun; 15 (2 Suppl): 4-7. 4. Hercogova J, Johnson R W, Current management of Herpes Zoster - The European view, Am J Clin Dermatol 2006;6 (5): 317-325. 5. Ragozzino MW, Melton LJ, Kurland LT, et all. Population based study of herpes zoster and its sequleae. Medicine (Baltimore) 1982; 61 (5): 310-6. 6. Guess HA, Broughton DD, Melton LJ, et all. Epidemiology of herpes zoster in children and adolescents: a population based study. Pediatrics 1985; 76 (4): 512-7. 7. Gnann JW, Whitley RJ. Clinical practice. Herpes zoster. N Engl Med. 2002; 347 (5): 340-346. 8. Thomas SL, Hall A J. What does epidemiology tells us about risk factors for herpes zoster? Lancet Infect. Dis. 2004; 4 (1): 26-33. 9. Kost RG, Straus SE. Postherpetic neuralgia: pathogenesis, treatment and prevention. N Engl Med 1996; 335 (1): 32-43. 10. Volpi A., Grass G, A.M. Arvin, Clinical Mikrobiology Reviews, July 1996, vol. 9, No 3, p. 361-368. 11. Gwieździński Z., Protas-Drozd F.: Nowoczesne leczenie półpaśca. Przew. Lek. 2000, 9. 58-60. 12. Tidwell E., Hutson B., Burkhart N., Gutmann J.L., Ellis C.D.: Herpes zoster of trigeminal nerve third branch: a case report and review of the literature. Int. Endod. J. 1999, 32, 61-66. 13. Gershon A.A.: Prevention and treatment of VZV infections in patients with HIV. Herpes 2001, 8, 32-6. 14. Gourishankar S. i wsp.: Herpes zoster infection following solid organ transplantation: incidence, risk factors and outcomes in the current immunosuppressive era. Am J Transplant 2004, 4, 108-15. 15. Thomson K.J i wsp.: The effect of low-dose aciclovir on reactivation of varicella-zoster virus after allogeneic haemopoietic stem cell transplantation. Bone Marrow Transplant 2005, 35, 1065-9. 16. Buntinx F., Wachana R., Bartholomeeusen S., Sweldens K., Geys H.: Is herpes zoster a marker for occult or subsequent malignancy? Br. J. Gen. Pract. 2005; 55: 102-107. 17. Martin W.J., Stoneburner J.: Symptomatic relief of herpetic skin lesions utilizing an energy-based approach to healing. Exp. Mol. Pathol. 2005; 78: 131-134. 18. Bielan B.: What´s your assessment? Herpes zoster. Dermatol. Nurs. 2004; 16: 431-432. 19. Bennett G.J: Neuropathic pain in the orofacial region: clinical and research challenges. J. Orofac. Pain. 2004; 18: 281-286. 20. Cohen P., Guillevin L.: Vasculitis associated with viral infections. Presse Med. 2004; 33: 1371-1384. 21. Hardy D.: Relief of pain in acute herpes zoster by nerve blocks and possible prevention of post-herpetic neuralgia. Can. J. Anaesth. 2005; 52: 186-190. 22. Agudo R., Lopez-Ramos E., Alonso H., Gomez-Escalonilla C.I, Garcia-Albea E., Jimenez-Jimenez F.J.: Horner´s syndrome secondary to thoracic herpes zoster. Rev. neurol. 2004; 39: 1199. 23. Chamberlain M.C.: Leukemia and the nervous system. Curr. Oncol. Rep. 2005; 7: 66-73. 24. Nogueira R.G., Traynor B.: The neurology of varicella-zoster virus: a historical perspective. Arch. Neurol. 2004; 61: 1974-1977. 25. Lerman Y., Chodick G., Tepper S., Livni G., Ashkenazi S.: Seroepidemiology of varicella-zoster virus antibodies among health-care workers and day-care-center workers. Epidemiol. Infect. 2004; 132: 1135-1138. 26. Wróbel K., Żaba R.: Półpasiec - objawy i leczenie. Zakażenia 2004, 4. 52-61. 27. Radzikowski A., Gyrczuk E.: Acyklowir. Leczenie zakażeń HSV i VZV. Lek. Rodz. 2004, 9, 74-83.
otrzymano/received: 2008-07-12
zaakceptowano/accepted: 2008-08-18
Adres/address:
*Agnieszka Sajdak-Wojtaluk
Oddział Dermatologiczny, 1. Szpital Wojskowy
20-904 Lublin, Al. Racławickie 23
tel.: (0-81) 718-32-38
e-mail: agnieszka.sajdak@interia.pl
